



## **ASX Announcement**

**06 October 2021**

### **Appointment of Company Secretary**

MELBOURNE, AUSTRALIA (06 October 2021): Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing pezadeftide (formerly HXP124), as a potential new prescription topical treatment for onychomycosis, today announces that Ms Leanne Ralph has been appointed as Company Secretary effective immediately, replacing Ms Helen Molloy.

Ms Molloy remains with the Company in the role of Financial Controller. The board thanks Ms Molloy for her efforts in fulfilling the Company Secretary role through Hexima's ASX listing and to date.

**This announcement is authorised for release to ASX by Michael Aldridge, Chief Executive Officer and Managing Director.**

***Enquiries:***

Dr Nicole van der Weerden  
Chief Operating Officer  
[n.vanderweerden@hexima.com.au](mailto:n.vanderweerden@hexima.com.au)

***To join our email database and receive company announcements please [click here](#).***

**About Hexima**

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit [www.hexima.com.au](http://www.hexima.com.au). You can also find us on [Twitter](#) and [LinkedIn](#) or email us at [info@hexima.com.au](mailto:info@hexima.com.au).